Global Hypopharyngeal Cancer Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

Global Hypopharyngeal Cancer Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com




Global Hypopharyngeal Cancer Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypopharyngeal Cancer (Oncology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Hypopharyngeal Cancer – Drugs In Development, 2021, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.

Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies.

The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.

Report Highlights

Hypopharyngeal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and IND/CTA Filed stages are 6, 12, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hypopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypopharyngeal Cancer (Oncology)

Key Topics Covered:

  1. Introduction
  2. Hypopharyngeal Cancer – Overview
  3. Hypopharyngeal Cancer – Therapeutics Development
  4. Hypopharyngeal Cancer – Therapeutics Assessment
  5. Hypopharyngeal Cancer – Companies Involved in Therapeutics Development
  6. Hypopharyngeal Cancer – Drug Profiles
  7. Hypopharyngeal Cancer – Dormant Projects
  8. Hypopharyngeal Cancer – Discontinued Products
  9. Hypopharyngeal Cancer – Product Development Milestones
  10. Appendix

Companies Mentioned

  • Ascenta Therapeutics Inc
  • AstraZeneca Plc
  • Biomimetix JV LLC
  • Boehringer Ingelheim International GmbH
  • Checkmate Pharmaceuticals Inc
  • Dracen Pharmaceuticals Inc
  • Eisai Co Ltd
  • F-star Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech USA Inc
  • Genexine Inc
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Innate Pharma SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Mabpharm Ltd
  • Merck & Co Inc
  • Moderna Inc
  • Ono Pharmaceutical Co Ltd
  • RemeGen Co Ltd
  • Shanghai De Novo Pharmatech Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • VasGene Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/7v38js

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900